Cancer nanomedicine: progress, challenges and opportunities

Shi, Jinjun; Kantoff, Philip W.; Wooster, Richard; Farokhzad, Omid C.

doi:10.1038/nrc.2016.108

Cited by 4,484 publications

(3,484 citation statements)

References 244 publications

Supporting

Mentioning

3,309

Contrasting

Unclassified

Order By: Relevance

“…Dozens of nanomedicines, such as Doxil, have been approved by the Food and Drug Administration (FDA) 12. However, the nanoscale size of these nanomedicines critically restricts their penetration in the dense ECM of hypoxic solid tumors, delivery efficiency, and antitumor efficacy 13.…”

Section: Introductionmentioning

confidence: 99%

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells

Zhu

Huang

et al. 2018

Advanced Science

View full text Add to dashboard Cite

Hypoxia is a fundamental hallmark of solid tumors and helps contribute to chemotherapy resistance. Hyperbaric oxygen (HBO) therapy can overcome tumor hypoxia and promote chemotherapy antitumor efficacy; however, the simultaneous administration of some conventional chemotherapies, including doxorubicin (DOX), with HBO is considered an absolute contraindication. Here, DOX‐loaded liposome (Doxil) is coadministered with HBO to assess the safety and efficacy of this combination treatment. By overcoming tumor hypoxia, HBO not only improves Doxil tumor penetration by decreasing the collagen deposition but also sensitizes tumor cells to Doxil. As a result, the combination treatment synergistically inhibits H22 tumor growth, with a tumor inhibition rate of 91.5%. The combination of HBO with Doxil shows neither extra side effects nor promotion of tumor metastasis. These results collectively reveal that the combination of HBO with Doxil is an effective and safe treatment modality. As both HBO and Doxil are routinely used, their combination could quickly translate to clinical trials for patients with hypoxic solid tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells

Zhu

Huang

et al. 2018

Advanced Science

View full text Add to dashboard Cite

show abstract

“…[210] Recently, liposomal-based nanomedicines combining cytarabine and daunorubicin (Vyxeos/CPX-351) in clinical trial phase III have shown improved overall survival benefits in patients with high risk acute myeloid leukaemia, increased from 5.95 to 9.56 months. [14] Thus, these nanomedicines can only provide modest overall survival benefits to the patients. The majority of the clinically approved cancer nanomedicines are based on the concept of EPR, while some of them designed with ligand mediated active targeting to alter the behaviour in tumors are [203] in clinical trials, such as BIND-014 (Bind therapeutics), [211] MM-302 (Merrimack Pharmaceuticals), [212] and anti-EGFR immunoliposomes.…”

Section: Cancer Nanomedicines From the Clinical Medicine Perspectivementioning

confidence: 99%

“…Anti-cancer nanomedicines are rapidly emerging as a promising approach and offers the possibilities to the clinicians to overcome the limitations of current cancer therapy. [14][15][16][17] In this direction, an array of nanomedicines has been synthesized, engineered with different physiochemical properties, such as size, shape and surface chemistry, and formulated with a large variety of anti-cancer therapeutics, including surface modifications with, e.g., polyethylene glycol (PEG) or other coatings, in order to extend the circulation time of the nanomedicines in bloodstream. [18][19][20] Various targeting moieties, such as antibodies, peptides, sugars and proteins, have also been attached to nanomedicines in different ways to further facilitate their selective accumulation within the tumors.…”

Section: Introductionmentioning

confidence: 99%

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Balasubramanian

Liu

Hirvonen

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

show abstract

“…The role of nanomedicine in the targeting process has been relevant 4, 5, 6. Indeed, in the last two decades, a broad range of nanomaterials has been developed for targeted therapies.…”

mentioning

confidence: 99%

An Intravascular Magnetic Catheter Enables the Retrieval of Nanoagents from the Bloodstream

et al. 2018

View full text Add to dashboard Cite

The clinical adoption of nanoscale agents for targeted therapy is still hampered by the quest for a balance between therapy efficacy and side effects on healthy tissues, due to nanoparticle biodistribution and undesired drug accumulation issues. Here, an intravascular catheter able to efficiently retrieve from the bloodstream magnetic nanocarriers not contributing to therapy, thus minimizing their uncontrollable dispersion and consequently attenuating possible side effects, is proposed. The device consists of a miniature module, based on 27 permanent magnets arranged in two coaxial series, integrated into a clinically used 12 French catheter. This device can capture ≈94% and 78% of the unused agents when using as carriers 500 and 250 nm nominal diameter superparamagnetic iron oxide nanoparticles, respectively. This approach paves the way to the exploitation of new “high‐risk/high‐gain” drug formulations and supports the development of novel therapeutic strategies based on magnetic hyperthermia or magnetic microrobots.

show abstract

Cancer nanomedicine: progress, challenges and opportunities

Cited by 4,484 publications

References 244 publications

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

An Intravascular Magnetic Catheter Enables the Retrieval of Nanoagents from the Bloodstream

Contact Info

Product

Resources

About